CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrado, A. M.
Right arrow Articles by Bhalla, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrado, A. M.
Right arrow Articles by Bhalla, K.

Cell Growth & Differentiation, Vol 7, Issue 8 1087-1094, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis

AM Ibrado, Y Huang, G Fang and K Bhalla
Department of Medicine, Winship Cancer Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

Intracellularly, the anticancer drug taxol induces tubulin polymerization and mitotic arrest, followed by apoptosis. The DNA repair enzyme poly(ADP-ribose) polymerase (PARP) and lamins are known to be degraded during apoptosis. PARP is a substrate for the Yama protease, which is encoded by the CPP32 beta/ Yama gene, whereas lamins are degraded by the Yama and lamin proteases. In the present studies, we determined the effects of enforced overexpression of the antiapoptosis Bcl-xL protein on taxol-mediated microtubule and cell cycle perturbations, as well as on taxol-induced apoptosis and associated Yama protease activity in human myeloid leukemia HL-60 cells. Our data demonstrate that high Bcl-xL levels do not affect the microtubular bundling or mitotic arrest due to taxol but significantly inhibit the morphological, flow cytometric, and DNA fragmentation features associated with taxol-induced apoptosis. This resulted in a significant improvement in the survival of taxol-treated cells that possess high Bcl-xL levels. In the control HL-60 cells, following taxol treatment, whereas the mRNA of Yama was not induced, taxol-induced apoptosis was associated with Yama activation and PARP as well as lamin B1 degradation. These features were blocked by coculture of these cells with the cysteine protease inhibitor YVAD-cmk as well as in cells with overexpression of Bcl-xL. These results suggest that Bcl-xL antagonizes taxol-induced apoptosis by a mechanism that interferes with the activation of a key protease involved in the execution of apoptosis.


This article has been cited by other articles:


Home page
BloodHome page
J. Chen, W. Fiskus, K. Eaton, P. Fernandez, Y. Wang, R. Rao, P. Lee, R. Joshi, Y. Yang, R. Kolhe, et al.
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism
Blood, April 23, 2009; 113(17): 4038 - 4048.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Bali, P. George, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, A. Scuto, S. Annavarapu, W. Fiskus, et al.
Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Clin. Cancer Res., August 1, 2004; 10(15): 4991 - 4997.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. George, P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, et al.
Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Cancer Res., May 15, 2004; 64(10): 3645 - 3652.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. R. Jazirehi, X.-H. Gan, S. De Vos, C. Emmanouilides, and B. Bonavida
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis
Mol. Cancer Ther., November 1, 2003; 2(11): 1183 - 1193.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Nimmanapalli, E. O'Bryan, D. Kuhn, H. Yamaguchi, H.-G. Wang, and K. N. Bhalla
Regulation of 17-AAG--induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG--mediated down-regulation of Akt, Raf-1, and Src kinases
Blood, July 1, 2003; 102(1): 269 - 275.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res., January 1, 2003; 63(1): 93 - 99.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Mabuchi, M. Ohmichi, A. Kimura, K. Hisamoto, J. Hayakawa, Y. Nishio, K. Adachi, K. Takahashi, E. Arimoto-Ishida, Y. Nakatsuji, et al.
Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel
J. Biol. Chem., September 6, 2002; 277(36): 33490 - 33500.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
T. A. Stadheim, N. Suh, N. Ganju, M. B. Sporn, and A. Eastman
The Novel Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) Potently Enhances Apoptosis Induced by Tumor Necrosis Factor in Human Leukemia Cells
J. Biol. Chem., May 10, 2002; 277(19): 16448 - 16455.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Guo, R. Nimmanapalli, S. Paranawithana, S. Wittman, D. Griffin, P. Bali, E. O'Bryan, C. Fumero, H. G. Wang, and K. Bhalla
Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis
Blood, May 1, 2002; 99(9): 3419 - 3426.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Shah and G. K. Schwartz
Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy
Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Nimmanapalli, E. O'Bryan, and K. Bhalla
Geldanamycin and Its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-Abl Levels and Induces Apoptosis and Differentiation of Bcr-Abl-positive Human Leukemic Blasts
Cancer Res., March 1, 2001; 61(5): 1799 - 1804.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
R. Nimmanapalli, M. Porosnicu, D. Nguyen, E. Worthington, E. O'Bryan, C. Perkins, and K. Bhalla
Cotreatment with STI-571 Enhances Tumor Necrosis Factor {{alpha}}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells
Clin. Cancer Res., February 1, 2001; 7(2): 350 - 357.
[Abstract] [Full Text]


Home page
BloodHome page
J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington, and K. Bhalla
Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
Blood, December 1, 2000; 96(12): 3900 - 3906.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Fang, C. N. Kim, C. L. Perkins, N. Ramadevi, E. Winton, S. Wittmann, and K. N. Bhalla
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
Blood, September 15, 2000; 96(6): 2246 - 2253.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Stiewe, K. Parssanedjad, H. Esche, B. Opalka, and B. M. Putzer
E1A Overcomes the Apoptosis Block in BCR-ABL+ Leukemia Cells and Renders Cells Susceptible to Induction of Apoptosis by Chemotherapeutic Agents
Cancer Res., July 1, 2000; 60(14): 3957 - 3964.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
C. L. Perkins, G. Fang, C. N. Kim, and K. N. Bhalla
The Role of Apaf-1, Caspase-9, and Bid Proteins in Etoposide- or Paclitaxel-induced Mitochondrial Events during Apoptosis
Cancer Res., March 1, 2000; 60(6): 1645 - 1653.
[Abstract] [Full Text]


Home page
BloodHome page
C. Perkins, C. N. Kim, G. Fang, and K. N. Bhalla
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL
Blood, February 1, 2000; 95(3): 1014 - 1022.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Motwani, T. M. Delohery, and G. K. Schwartz
Sequential Dependent Enhancement of Caspase Activation and Apoptosis by Flavopiridol on Paclitaxel-treated Human Gastric and Breast Cancer Cells
Clin. Cancer Res., July 1, 1999; 5(7): 1876 - 1883.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Gibson, C. Widmann, and G. L. Johnson
Differential Involvement of MEK Kinase 1 (MEKK1) in the Induction of Apoptosis in Response to Microtubule-targeted Drugsversus DNA Damaging Agents
J. Biol. Chem., April 16, 1999; 274(16): 10916 - 10922.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
T.-H. Wang, D. M. Popp, H.-S. Wang, M. Saitoh, J. G. Mural, D. C. Henley, H. Ichijo, and J. Wimalasena
Microtubule Dysfunction Induced by Paclitaxel Initiates Apoptosis through Both c-Jun N-terminal Kinase (JNK)-dependent and -Independent Pathways in Ovarian Cancer Cells
J. Biol. Chem., March 19, 1999; 274(12): 8208 - 8216.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M. Keane, S. A. Ettenberg, M. M. Nau, E. K. Russell, and S. Lipkowitz
Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines
Cancer Res., February 1, 1999; 59(3): 734 - 741.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. P. Amarante-Mendes, C. Naekyung Kim, L. Liu, Y. Huang, C. L. Perkins, D. R. Green, and K. Bhalla
Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3
Blood, March 1, 1998; 91(5): 1700 - 1705.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. H. Kaufmann, J. E. Karp, P. A. Svingen, S. Krajewski, P. J. Burke, S. D. Gore, and J. C. Reed
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Blood, February 1, 1998; 91(3): 991 - 1000.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. E. Frankel, P. D. Hall, C. Burbage, J. Vesely, M. Willingham, K. Bhalla, and R. J. Kreitman
Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein
Blood, November 1, 1997; 90(9): 3654 - 3661.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Los, I. Herr, C. Friesen, S. Fulda, K. Schulze-Osthoff, and K.-M. Debatin
Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases)
Blood, October 15, 1997; 90(8): 3118 - 3129.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Chhanabhai, S. Krajewski, M. Krajewska, H.-G. Wang, J. C. Reed, and R. D. Gascoyne
Immunohistochemical Analysis of Interleukin-1beta -Converting Enzyme/Ced-3 Family Protease, CPP32/Yama/Caspase-3, in Hodgkin's Disease
Blood, September 15, 1997; 90(6): 2451 - 2455.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. M. Martins, T. Kottke, P. W. Mesner, G. S. Basi, S. Sinha, N. Frigon Jr., E. Tatar, J. S. Tung, K. Bryant, A. Takahashi, et al.
Activation of Multiple Interleukin-1{beta} Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis
J. Biol. Chem., March 14, 1997; 272(11): 7421 - 7430.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.